Exubera, Ionsys get CHMP positive opinions

The EMEA's CHMP issued a positive opinion to sanofi-aventis (Euronext:SAN; SNY) and Pfizer (PFE) for Exubera inhaled insulin powder to treat Type I and Type II diabetes. Exubera also is under FDA review with an undisclosed PDUFA date. Last month, an FDA panel voted in favor of approval of Exubera in the same indications (see BioCentury, Sept. 12, 2005). Nektar (NKTR) developed and provides the inhalers and the powdered insulin for Exubera. NKTR was up $1.08 to $16.08 on Wednesday. ...